Tilray Brands (NASDAQ:TLRY) Trading Down 2% – Here’s What Happened

Tilray Brands, Inc. (NASDAQ:TLRY) traded down 2% during trading on Tuesday . The company traded as low as $7.17 and last traded at $7.20. 2,521,470 shares changed hands during trading, a decline of 38% from the average session volume of 4,054,649 shares. The stock had previously closed at $7.35.

Key Headlines Impacting Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Tilray Pharma struck a strategic alliance with Tilray Medical, CC Pharma, 14U Pharma and the “gesund leben” cooperation operated by Alliance Healthcare Deutschland to expand pharmacy access across Germany (network serves >10,000 pharmacies via 27 logistics centers). This materially improves Tilray’s European pharmaceutical distribution scale and could accelerate Rx and OTC sales in a large, high-value market. Tilray Medical…Strengthen Pharmacy Access Across Germany
• Positive Sentiment: Tilray’s Pub Beer brand launched “Pub Light,” a low-calorie (99 cal), 4% ABV light lager aimed at price- and health-conscious consumers in the Pacific Northwest. This product expands the beverage portfolio, targets mass-market demand for light beers, and demonstrates brand-extension activity in consumer packaged goods. Lighter. Cheaper. Funner. Pub Light Is Here.
• Neutral Sentiment: Brokerage consensus remains a “Hold,” indicating limited near-term analyst enthusiasm despite product and distribution news; this suggests investors may wait for clearer revenue/margin impact before re-rating the stock. Tilray Brands…Given Consensus Rating of “Hold”
• Neutral Sentiment: Coverage includes broader beverage-industry headlines (e.g., BrewDog reporting issues) that may create sector noise but are not directly tied to Tilray’s fundamentals. BrewDog had no money left when we rescued it, says US buyer
• Negative Sentiment: Tilray still carries profitability and analyst-forecast headwinds: recent quarterly results showed a revenue beat but very negative net margins and the street expects ~-0.2 EPS for the year. Those fundamentals limit how much positive distribution or product news will immediately lift the stock until revenue growth and margins improve.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. ATB Cormark Capital Markets upgraded Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 10th. Roth Mkm lowered their price target on Tilray Brands from $20.00 to $10.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 20th. Zacks Research upgraded Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tilray Brands in a research note on Wednesday, January 21st. Finally, Canaccord Genuity Group started coverage on Tilray Brands in a report on Tuesday, January 27th. They set a “hold” rating on the stock. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Tilray Brands presently has a consensus rating of “Hold” and a consensus price target of $13.33.

Tilray Brands Stock Down 3.7%

The company has a debt-to-equity ratio of 0.19, a current ratio of 2.81 and a quick ratio of 1.72. The stock has a market capitalization of $810.33 million, a P/E ratio of -0.31 and a beta of 1.96. The stock’s fifty day moving average is $8.18 and its two-hundred day moving average is $10.87.

Tilray Brands (NASDAQ:TLRY) last posted its quarterly earnings results on Thursday, January 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.12. The company had revenue of $217.51 million for the quarter, compared to analysts’ expectations of $211.15 million. Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.During the same quarter in the prior year, the company earned ($0.03) earnings per share. As a group, research analysts predict that Tilray Brands, Inc. will post -0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tilray Brands

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Optiver Holding B.V. raised its holdings in Tilray Brands by 239.4% during the 3rd quarter. Optiver Holding B.V. now owns 224,049 shares of the company’s stock worth $388,000 after buying an additional 158,041 shares during the period. Cresset Asset Management LLC boosted its holdings in shares of Tilray Brands by 72.1% in the third quarter. Cresset Asset Management LLC now owns 501,989 shares of the company’s stock worth $868,000 after buying an additional 210,267 shares during the period. Quinn Opportunity Partners LLC boosted its holdings in shares of Tilray Brands by 11.6% in the second quarter. Quinn Opportunity Partners LLC now owns 1,918,080 shares of the company’s stock worth $795,000 after buying an additional 200,000 shares during the period. HighPoint Advisor Group LLC purchased a new position in shares of Tilray Brands in the third quarter worth approximately $33,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in shares of Tilray Brands by 82.3% during the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 59,231 shares of the company’s stock valued at $102,000 after acquiring an additional 26,733 shares during the period. Institutional investors and hedge funds own 9.35% of the company’s stock.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.